Loading
Lung Cancer Research Studies · Journal article
Clinical Nuclear Medicine · September 4, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a single-case report of a 54-year-old man with progressive small cell lung cancer evaluated with dual PET/CT imaging (¹⁸F-FDG and ⁶⁸Ga-DOTATATE) before radionuclide therapy. The case demonstrates discordant uptake patterns between the two tracers, suggesting tumor heterogeneity and complementary diagnostic roles, but provides no evidence on clinical outcomes, patient selection validity, or comparative effectiveness.
Single-case report. One 54-year-old man with progressive small cell lung cancer referred for radionuclide therapy planning. Intervention: ¹⁸F-FDG PET/CT and ⁶⁸Ga-DOTATATE PET/CT imaging performed before radionuclide therapy. n = 1.
¹⁸F-FDG PET/CT identified metabolically active lesions indicating disease extent ⁶⁸Ga-DOTATATE PET/CT showed high SSTR expression in bone lesions and pancreatic tail Discordant hepatic uptake between the two imaging modalities suggested tumor heterogeneity
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This case illustrates a potential imaging strategy combining ¹⁸F-FDG and ⁶⁸Ga-DOTATATE PET/CT for patient selection and treatment planning in SSTR-targeted radionuclide therapy; however, the single-case nature and absence of outcome data mean clinicians cannot yet determine whether dual imaging affects treatment efficacy, patient selection accuracy, or clinical outcomes.
Single-case report demonstrating imaging methodology and concordance patterns in one patient; raises questions about imaging selection and tumor heterogeneity but lacks comparative data, control group, or outcome data to establish clinical utility.
As stated by the source record.
Quoted from the source exactly as published.
This case illustrates a potential imaging strategy combining ¹⁸F-FDG and ⁶⁸Ga-DOTATATE PET/CT for patient selection and treatment planning in SSTR-targeted radionuclide therapy; however, the single-case nature and absence of outcome data mean clinicians cannot yet determine whether dual imaging affects treatment efficacy, patient selection accuracy, or clinical outcomes.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
A 54-year-old man with progressive small cell lung cancer underwent ¹⁸F-FDG and ⁶⁸Ga-DOTATATE PET/CT before radionuclide therapy. ¹⁸F-FDG PET/CT evaluated disease extent and identified metabolically active lesions. ⁶⁸Ga-DOTATATE PET/CT showed high SSTR expression in bone lesions and the pancreatic tail. Discordant hepatic uptake suggested tumor heterogeneity. The two scans provided complementary information on disease activity and therapeutic target expression, supporting patient selection and individualized planning for an SSTR-targeted radionuclide therapy-based comprehensive treatment strategy.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.